Literature DB >> 29247481

Pityriasis rubra pilaris: algorithms for diagnosis and treatment.

S Roenneberg1, T Biedermann1.   

Abstract

Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages and also children. The clinical appearance of PRP is highly variable, as is the individual prognosis. Therefore, stratifying PRP into six disease subtypes represents a first step to personalized medicine for this rare inflammatory skin disease. The next step should be to associate specific therapeutic strategies with these subtypes of PRP. However, no randomized, controlled trials on the treatment of PRP have been performed. Consequently, the actual treatment algorithm for PRP will be based on clinical experience, small case series and case reports. The majority of published evidence is on type I PRP, whereas the treatment experience for other clinical types of PRP is still sparse and has to be gained. Nevertheless, it is now time to start developing valid algorithms as a basis for the diagnosis and treatment of PRP based on the data available. This review makes use of algorithms developed in psoriasis and atopic eczema and puts together recent insights into the pathogenesis, diagnosis and treatment experience of PRP. The innovative intention of this appraisal is to develop a structured algorithm for PRP treatment that should be further developed going forward.
© 2017 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2018        PMID: 29247481     DOI: 10.1111/jdv.14761

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

1.  Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: a case report and its dermoscopic features.

Authors:  D Kadylak; W Barańska-Rybak
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-06-11       Impact factor: 9.228

2.  What's driving dermatology? Contribution title analysis of the largest German Dermatology Congress 2019.

Authors:  Robert Kaczmarczyk; Felix King; Tilo Biedermann; Alexander Zink
Journal:  Digit Health       Date:  2021-04-21

3.  Pityriasis rubra pilaris post-infection due COVID-19: case report.

Authors:  Franklin R Aguilar-Gamboa; Dennis Cubas-Alarcon; Miguel Villegas-Chiroque; Virgilio E Failoc-Rojas
Journal:  Colomb Med (Cali)       Date:  2021-03-18

4.  Pityriasis rubra pilaris potentially triggered by messenger RNA-1273 COVID vaccine.

Authors:  Etsubdenk M Ajebo; John D Howard; Dipti Anand; Loretta S Davis
Journal:  JAAD Case Rep       Date:  2022-04-01

5.  Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin.

Authors:  Medek Katharina; Selhofer Sylvia; Buchner Matthias; Mrowietz Ulrich; Laimer Martin
Journal:  Pediatr Dermatol       Date:  2022-07-20       Impact factor: 1.997

6.  Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab.

Authors:  Kathrin Hanfstingl; Agnes Pekar-Lukacs; Reinhard Motz; Emmanuella Guenova; Wolfram Hoetzenecker
Journal:  Case Rep Dermatol       Date:  2018-05-02

7.  Pityriasis rubra pilaris in skin of color.

Authors:  John G Plante; Ahmad I Aleisa; Bruce H Thiers
Journal:  Int J Womens Dermatol       Date:  2021-01-19

8.  Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: Decoding a possible trigger!!

Authors:  Aakanksha Arora; Alpana Mohta; Bhikam Chand Ghiya; Vishnu Kumar Jangir
Journal:  J Cosmet Dermatol       Date:  2022-04-09       Impact factor: 2.189

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.